Allarity Granted U.S. Patent for Stenoparib Dosing Regimen
The USPTO granted Allarity a patent covering twice-daily stenoparib dosing, extending to 2045, supporting its Phase 2 program in ovarian and other solid tumors. This IP strengthens the company's pipeline as it advances pivotal trials.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed